Pharmosa Biopharm Inc. (6875.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Pharmosa Biopharm Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 167.57 m TWD | 67.27 m TWD |
| Gross profit | 126.90 m TWD | 13.03 m TWD |
| Operating income | -218.57 m TWD | -402.86 m TWD |
| EBIT | -164.23 m TWD | -381.75 m TWD |
| Net income | -166.65 m TWD | -383.85 m TWD |
| Diluted EPS – continuing operations | -1.29 TWD | -2.97 TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
More stocks
- CURATIS N AG (CURN.SW)
- Perspective Therapeutics, Inc. (CATX)
- SPSoft Inc. (443670.KQ)
- Shinhung (004080.KS)
- AEWIN Technologies Co.Ltd. (3564.TWO)
- Patria Bank SA (PBK.RO)
- Chin Hsin Environ Engineering Co., Ltd. (6951.TW)
- Unicycive Therapeutics, Inc. (UNCY)
- QUALITAS SEMICONDUCTOR CO. LTD. (432720.KQ)
- GEORGE RISK INDUSTRIES, INC. (RSKIA)
- G2Power Co. Ltd. (388050.KQ)
- Karex Berhad (5247.KL)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.